Schwartz Investment Counsel Inc. Has $5.21 Million Stock Position in Haemonetics Corporation $HAE

Schwartz Investment Counsel Inc. lessened its position in shares of Haemonetics Corporation (NYSE:HAE) by 52.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,000 shares of the medical instruments supplier’s stock after selling 72,250 shares during the quarter. Schwartz Investment Counsel Inc. owned approximately 0.14% of Haemonetics worth $5,210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Central Pacific Bank Trust Division boosted its stake in Haemonetics by 2.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after buying an additional 188 shares in the last quarter. Quantinno Capital Management LP raised its holdings in shares of Haemonetics by 9.0% in the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after buying an additional 289 shares in the last quarter. Cardinal Capital Management lifted its position in shares of Haemonetics by 1.5% during the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after buying an additional 321 shares during the period. True Wealth Design LLC grew its position in Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 335 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Haemonetics by 0.8% during the third quarter. Envestnet Asset Management Inc. now owns 40,174 shares of the medical instruments supplier’s stock valued at $1,958,000 after acquiring an additional 338 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Trading Up 3.4%

Shares of HAE opened at $54.02 on Wednesday. The stock’s fifty day simple moving average is $59.00 and its 200-day simple moving average is $66.73. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $2.51 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 1.05 and a beta of 0.53. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, research analysts predict that Haemonetics Corporation will post 5.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on HAE shares. Robert W. Baird set a $67.00 price target on shares of Haemonetics in a report on Friday. BTIG Research reiterated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Barrington Research decreased their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday. Mizuho cut their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Finally, JPMorgan Chase & Co. lowered their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $79.33.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.